◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

VISEN Pharmaceuticals (2561) Financial History

Name: VISEN Pharmaceuticals (2561) financial statement history
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Drug Manufacturers - Specialty & Generic · DATA UPDATED 2026-08-10

VISEN Pharmaceuticals (2561) operates in the Drug Manufacturers - Specialty & Generic industry and is headquartered in Suzhou, China with about 82 employees. Its market capitalization is roughly CNY 2 billion. In the fiscal year ended 2025-12-31, 2561 reported CNY 0M in revenue and (CNY 253M) in net income.

VISEN Pharmaceuticals, an investment holding company, engages in the development and commercialization of paradigm-shifting endocrine therapies in the Chinese Mainland.

Interactive charts & full statements →

2561 Revenue & Earnings History — Annual Income Statement

Income statement	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Total Revenue	CNY 0M	CNY 0M	CNY 0M	CNY 0M
Gross Profit	CNY 0M	CNY 0M	—	—
Operating Income (EBIT)	(CNY 240M)	(CNY 174M)	(CNY 139M)	(CNY 358M)
Net Income	(CNY 253M)	(CNY 182M)	(CNY 250M)	(CNY 289M)

CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

2561 Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2024-12-31
Total Revenue	CNY 0M
Operating Income (EBIT)	(CNY 54M)
Net Income	(CNY 53M)

CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

2561 Free Cash Flow History

2561 Balance Sheet History

Balance sheet	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Total Assets	CNY 977M	CNY 294M	CNY 444M	CNY 741M
Total Liabilities	CNY 215M	CNY 52M	CNY 53M	CNY 89M

CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 2561 viewer.

Other Companies in Drug Manufacturers - Specialty & Generic

BCRX · BioCryst Pharmaceuticals, Inc. — $2 billion
RGC · Regencell Bioscience Holdings Limited — $2 billion
6896 · Golden Throat Holdings Group Company Limited — $2 billion
PBH · Prestige Consumer Healthcare Inc. — $2 billion
BHC · Bausch Health Companies Inc. — $2 billion
2633 · Jacobson Pharma Corporation Limited — $2 billion
DMP · Dermapharm Holding SE — $2 billion
PRGO · Perrigo Company plc — $2 billion

← 2560 All “0-9” companies 2562 →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.